Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:968681.
doi: 10.1155/2014/968681. Epub 2014 Feb 4.

New insight into the molecular drug target of diabetic nephropathy

Vivian Soetikno  1 , Wawaimuli Arozal  1 , Melva Louisa  1 , Rianto Setiabudy  1
Affiliations
Review

New insight into the molecular drug target of diabetic nephropathy

Vivian Soetikno et al. Int J Endocrinol. 2014.

Abstract

Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic illustration of the interaction between hemodynamic and metabolic factors in the pathophysiology of diabetic nephropathy.
Figure 2
Figure 2
Current drug targets in diabetic nephropathy. Interrelated derangements in cellular hemodynamic, metabolic, oxidative stress, inflammation; lipid dysfunction, and extracellular matrix accumulation occur in diabetes and lead to diabetic nephropathy. These derangements provide the targets for the development of mechanism based drugs.
See this image and copyright information in PMC

References

    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 2010;87(1):4–14. - PubMed
    1. Pramono LA, Setiati S, Soewondo P, et al. Prevalence and predictors of undiagnosed diabetes mellitus in Indonesia. Acta Medica Indonesiana. 2010;42(4):216–223. - PubMed
    1. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. Journal of Diabetes Research. 2013;2013:8 pages.248563 - PMC - PubMed
    1. Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. Advances in Chronic Kidney Disease. 2013;20(5):390–395. - PubMed
    1. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clinic Proceedings. 2011;86(5):444–456. - PMC - PubMed

LinkOut - more resources